What is HC Wainwright's Forecast for MLTX Q1 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for shares of MoonLake Immunotherapeutics in a note issued to investors on Thursday, February 27th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.77) per share for the quarter, down from their previous forecast of ($0.69). HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.72) EPS and FY2025 earnings at ($3.00) EPS.

Several other research firms have also recently commented on MLTX. Needham & Company LLC raised their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group dropped their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $83.20.

MoonLake Immunotherapeutics Stock Down 0.4 %

Shares of NASDAQ:MLTX traded down $0.17 on Monday, hitting $39.82. The company had a trading volume of 134,832 shares, compared to its average volume of 341,686. The firm's 50-day simple moving average is $45.74 and its two-hundred day simple moving average is $48.78. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $58.26. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -30.87 and a beta of 1.28.

Remove Ads

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.09).

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of MoonLake Immunotherapeutics by 96.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,814 shares of the company's stock worth $1,806,000 after acquiring an additional 17,580 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of MoonLake Immunotherapeutics in the 3rd quarter worth about $741,000. Barclays PLC increased its stake in MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company's stock valued at $283,000 after purchasing an additional 5,229 shares in the last quarter. State Street Corp increased its stake in MoonLake Immunotherapeutics by 96.2% during the 3rd quarter. State Street Corp now owns 87,637 shares of the company's stock valued at $4,419,000 after purchasing an additional 42,980 shares in the last quarter. Finally, Congress Asset Management Co. increased its stake in MoonLake Immunotherapeutics by 9.5% during the 4th quarter. Congress Asset Management Co. now owns 72,993 shares of the company's stock valued at $3,953,000 after purchasing an additional 6,352 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.